Jazz Pharma FY23 net income $414.8M vs loss; guides FY24 rev $4.0-4.2B

Jazz Pharmaceuticals plc

2023-FY EPS reported $6.10 revenue$3,834,204,000

Total revenue $3.84B in 2023, up 5% YoY; Q4 revenue $1.01B, up 4% YoY.
GAAP EPS $6.10; non-GAAP adjusted EPS $18.29, vs. $13.20 in 2022.
Key growth drivers: Xywav +33%, Epidiolex +15%, Rylaze +40% in 2023.
2024 guidance: revenue $4.0-4.2B, non-GAAP adjusted EPS $18.15-19.35.
Oncology revenue surpassed $1B in 2023; $161M remains for share buybacks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.